George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Https://apple.news/A3mCY7C6zS3iwrIi2C-dN2g
Good article on the process
Hi all,
Not getting the chance to post much of late but still review posts every few days.
Question
When we went for clinical trails for CHK1, we had to fund £800k (2016) as our percentage (27.5%)of the trial before it commenced, but this time we have received approval with no mention of funding the trials.
Looking at cash, we must be around £1.4m looking at cash burn and 2022 results.
Therefore is the price being held back whilst a placing is being completed which we will hear of shortly or are costs far less on the initial phase and we are confident we can fund ourselves initially knowing we have done cash coming in shortly?
Appreciate the long term holders thoughts
Steve
Andy,
I hope you are well!
I’m 2008 ??, but 100% behind Sareum and can’t believe the current price, been trading a few for last few years and benefited from a new car for wife and some nice holidays. Currently playing with 30k bought at 0.96 with a target price of £3-3.50 over the next few months ??
Sasanof-1 well spudding
Clontarf Energy plc (AIM: CLON),is pleased to provide the following operational update on the drilling of the Sasanof-1 exploration well:
· Drilling of Sasanof-1 well has now started.
· The well was spudded with the jetting of the 36" conductor at a water depth 1,068.3 metres (below mean sea level "BMSL").
· Drilling is now underway on the 17-1/2" intermediate hole section to a depth of 2,030m (BMSL), 13-3/8" casing will then be run and cemented.
· This will be followed by the drilling the 12-1/4" hole section through the target reservoir section to a total depth of 2,500 metres (BMSL).
The current schedule expects drilling through the target reservoir occurring, at earliest, between Thursday 2nd and Sunday 5th June.
Further updates will be provided upon the completion of campaign milestones.
Hi Stoney,
Agree (13 years for me) but think it might takes a few weeks ( mid July for me) before we see results but never seen the bod so relaxed and even driving SP up with recent placing. It’s taken a bit longer than I’m sure we anticipated when we invested but the rewards now are mind blowing for us all. Just need the confirmation of trial results and then the news to get behind it and I honestly do know where we can get too in SP but the 10p is now seriously under estimated but was agreed 7-8 years ago ??. Good luck everyone, not posting much over the last few years due to work commitments but look in daily at the great posts from some truly well researched people
SDC-1801 – Autoimmune diseases & Covid-19
• Good efficacy in RA and Psoriasis disease models
• Initial toxicology studies completed
• Aiming to complete tox studies and file an exploratory CTA in H2 2021*
• Projected Phase 1 start early 2022*
• Manufacturing route completed
Last line says it all!
RNS was dated 26th March
Wording suggests we should of already received the payment if due within 9 months or can cancel contract which would suggest Chinese wouldn’t risk not paying on time if they have got it to work..... RNS due.....?
Under the terms of the Agreement, the Licensee will fund all future development activities in relation to the Compounds and has been granted sole rights to market any resulting products worldwide.
Sareum will receive an initial upfront payment of approximately £50,000. A further payment of approximately £0.9 million will be payable to Sareum if certain milestones related to the oral bioavailability of the Compounds are achieved within nine months from the date of the Agreement (the "Development Payment").
Sareum will assign certain patents in respect of the Compounds to the Licensee upon receipt of the Development Payment. The Agreement may be terminated with immediate effect if Sareum does not receive the Development Payment within nine months of the date of the Agreement.
Portfolio update June 19
Sareum's recent activities have focused on toxicology studies designed to gain insight to the maximum-tolerated doses (MTD) of SDC-1801 and SDC-1802 in rodents. SDC-1801 is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; an MTD has yet to be reached.